Squarepoint
FULC icon

Squarepoint’s Fulcrum Therapeutics FULC Stock Holding History

Squarepoint’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Buy
175,944
+110,092
+167% +$1.02M ﹤0.01% 2514
2025
Q4 		$745K Buy
65,852
+48,026
+269% +$489K ﹤0.01% 2863
2025
Q3 		$164K Buy
17,826
+4,151
+30% +$30K ﹤0.01% 4001
2025
Q2 		$94.1K Buy
+13,675
New +$73.1K ﹤0.01% 4179
2024
Q4 		– Sell
-88,130
Closed -$325K – 5174
2024
Q3 		$315K Buy
88,130
+63,613
+259% +$472K ﹤0.01% 3407
2024
Q2 		$152K Sell
24,517
-30,043
-55% -$228K ﹤0.01% 3725
2024
Q1 		$515K Buy
+54,560
New +$487K ﹤0.01% 3029
2023
Q4 		– Sell
-58,900
Closed -$262K – 4166
2023
Q3 		$262K Sell
58,900
-41,891
-42% -$183K ﹤0.01% 3262
2023
Q2 		$333K Sell
100,791
-218,920
-68% -$643K ﹤0.01% 2901
2023
Q1 		$911K Buy
+319,711
New +$2.86M ﹤0.01% 1959
2022
Q3 		– Sell
-30,936
Closed -$152K – 3143
2022
Q2 		$152K Buy
30,936
+567
+2% +$5.54K ﹤0.01% 2545
2022
Q1 		$718K Buy
30,369
+11,140
+58% +$158K ﹤0.01% 1793
2021
Q4 		$340K Buy
+19,229
New +$381K ﹤0.01% 2379
2020
Q2 		– Sell
-13,878
Closed -$166K – 2320
2020
Q1 		$166K Buy
+13,878
New +$222K ﹤0.01% 1536

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Squarepoint's FULC Position: Q1 2026 in Review

Squarepoint increased its Fulcrum Therapeutics (FULC) stake by 167% in Q1 2026, buying an estimated $1.02M and bringing the position to 175,944 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Squarepoint first reported a position in FULC in Q1 2020 and has held it in 14 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Squarepoint held 175,944 shares of Fulcrum Therapeutics worth $1.35M as of Q1 2026.
  • Squarepoint bought 110,092 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Fulcrum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2514 holding.
  • Squarepoint first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.